▶ 調査レポート

神経診断のグローバル市場(~2027):臨床検査機器、診断&画像システム、試薬&消耗品

• 英文タイトル:Neurodiagnostics Market Research Report by Product, Indication, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Neurodiagnostics Market Research Report by Product, Indication, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「神経診断のグローバル市場(~2027):臨床検査機器、診断&画像システム、試薬&消耗品」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2304A016
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、222ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の当調査レポートでは、2021年に6,237.21百万ドルであった世界の神経診断市場規模が2022年に6,763.48百万ドルへと拡大、更に2027年までにCAGR 8.61%で成長して10,240.45百万ドルに達すると予測しています。当書は、神経診断の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析(臨床検査機器、診断&画像システム、試薬&消耗品)、疾患別分析(てんかん、頭痛、神経変性疾患、睡眠障害、脳卒中)、エンドユーザー別分析(診断検査室&画像センター、病院&クリニック、外来診療センター、神経センター)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの構成でまとめています。なお、当書には、Advanced Brain Monitoring, Inc.、Bio-Rad Laboratories、Canon, Inc.、F. Hoffmann-La Roche AG、FUJIFILM Holdings Corporation、GE Healthcare、Hitachi, Ltd.、Lifelines Neuro Company, LLC、Mitsar Co., Ltd.、Natus Medical Incorporated、Nihon Kohden Corporation、Philips Healthcareなどの企業情報が含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の神経診断市場規模:製品別
- 臨床検査機器の市場規模
- 診断&画像システムの市場規模
- 試薬&消耗品の市場規模
・世界の神経診断市場規模:疾患別
- てんかんにおける市場規模
- 頭痛における市場規模
- 神経変性疾患における市場規模
- 睡眠障害における市場規模
- 脳卒中における市場規模
・世界の神経診断市場規模:エンドユーザー別
- 診断検査室&画像センターにおける市場規模
- 病院&クリニックにおける市場規模
- 外来診療センターにおける市場規模
- 神経センターにおける市場規模
・世界の神経診断市場規模:地域別
- 南北アメリカの神経診断市場規模
アメリカの神経診断市場規模
カナダの神経診断市場規模
ブラジルの神経診断市場規模
...
- アジア太平洋の神経診断市場規模
日本の神経診断市場規模
中国の神経診断市場規模
インドの神経診断市場規模
韓国の神経診断市場規模
台湾の神経診断市場規模
...
- ヨーロッパ/中東/アフリカの神経診断市場規模
イギリスの神経診断市場規模
ドイツの神経診断市場規模
フランスの神経診断市場規模
ロシアの神経診断市場規模
...
- その他地域の神経診断市場規模
・競争状況
・企業情報

The Global Neurodiagnostics Market size was estimated at USD 6,237.21 million in 2021 and expected to reach USD 6,763.48 million in 2022, and is projected to grow at a CAGR 8.61% to reach USD 10,240.45 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Neurodiagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Clinical Testing Instrument, Diagnostic & Imaging System, and Reagent & Consumable. The Clinical Testing Instrument is further studied across NGS Instrument, PCR Instrument, and Sanger Sequencer. The Diagnostic & Imaging System is further studied across Angiography System, CT Scanner, EEG System, EMG Device, MEG Device, MRI System, PET Scanner, and Ultrasound Imaging System. The Reagent & Consumable is further studied across Antibody, Buffer, Enzyme, Protein, & Peptide, Media & Sera, Probe, and Solvent.

Based on Indication, the market was studied across Epilepsy, Headache Disorder, Neurodegenerative Diseases, Sleep Disorder, and Stroke.

Based on End User, the market was studied across Diagnostic Laboratory & Imaging Center, Hospital & Clinic, Ambulatory Care Center, and Neurology Center.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Neurodiagnostics market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neurodiagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neurodiagnostics Market, including Advanced Brain Monitoring, Inc., Bio-Rad Laboratories, Canon, Inc., F. Hoffmann-La Roche AG, FUJIFILM Holdings Corporation, GE Healthcare, Hitachi, Ltd., Lifelines Neuro Company, LLC, Mitsar Co., Ltd., Natus Medical Incorporated, Nihon Kohden Corporation, Philips Healthcare, QIAGEN N.V., Siemens Healthineers, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Neurodiagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neurodiagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neurodiagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Neurodiagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Neurodiagnostics Market?
6. What is the market share of the leading vendors in the Global Neurodiagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Neurodiagnostics Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of neurological disorders worldwide
5.1.1.2. Growing awareness among patients for early disease diagnosis for effective treatment
5.1.1.3. Growing adoption of innovative diagnostic technologies
5.1.2. Restraints
5.1.2.1. Limited availability of skilled healthcare professionals
5.1.3. Opportunities
5.1.3.1. Advances in genomics and proteomics for neurodegenerative disorders diagnosis
5.1.3.2. Ongoing clinical trials
5.1.4. Challenges
5.1.4.1. High cost associated with the neurodiagnostic devices
5.2. Cumulative Impact of COVID-19

6. Neurodiagnostics Market, by Product
6.1. Introduction
6.2. Clinical Testing Instrument
6.3.1. NGS Instrument
6.3.2. PCR Instrument
6.3.3. Sanger Sequencer
6.3. Diagnostic & Imaging System
6.4.1. Angiography System
6.4.2. CT Scanner
6.4.3. EEG System
6.4.4. EMG Device
6.4.5. MEG Device
6.4.6. MRI System
6.4.7. PET Scanner
6.4.8. Ultrasound Imaging System
6.4. Reagent & Consumable
6.5.1. Antibody
6.5.2. Buffer
6.5.3. Enzyme, Protein, & Peptide
6.5.4. Media & Sera
6.5.5. Probe
6.5.6. Solvent

7. Neurodiagnostics Market, by Indication
7.1. Introduction
7.2. Epilepsy
7.3. Headache Disorder
7.4. Neurodegenerative Diseases
7.5. Sleep Disorder
7.6. Stroke

8. Neurodiagnostics Market, by End User
8.1. Introduction
8.2. Diagnostic Laboratory & Imaging Center
8.3. Hospital & Clinic
8.4. Ambulatory Care Center
8.5. Neurology Center

9. Americas Neurodiagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Neurodiagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Neurodiagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Advanced Brain Monitoring, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Bio-Rad Laboratories
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Canon, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. F. Hoffmann-La Roche AG
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. FUJIFILM Holdings Corporation
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. GE Healthcare
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Hitachi, Ltd.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Lifelines Neuro Company, LLC
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Mitsar Co., Ltd.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Natus Medical Incorporated
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Nihon Kohden Corporation
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Philips Healthcare
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. QIAGEN N.V.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Siemens Healthineers
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Thermo Fisher Scientific, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing